CTNNB1 and melanoma: Of interest, a CTNNB1 mutation at the same residue (S33C) has been reported to confer resistance to the KIT inhibitor imatinib in a patient with KIT L576P mutant melanoma (Cho et al., 2017) and therefore has direct clinical value.